Sanofi Sponsored ADR Aktie News

Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025

Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D patients Teizeild represents a potential significant change in the treatment of autoimmune T1D, preventing the natural disease progression protecting beta-cell function Paris, January 12, 2026. The E...

BrightInsight Patient App improved treatment adherence and decreased discontinuation rate for for one of Sanofi and Regeneron's key biologic therapies.

CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announced today that Sanofi is making a $30 million investment to accelerate Enable's manufacturing build-out, strengthen its supply chain capabilities, and drive commercial growth.

The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old.

Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1D Tzield slows disease progression by protecting the insulin-secreting beta cells of the pancreas The priority review is based on interim r...

Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors.